United States · Platforms & data · MarketWatch

Lilly raises outlook for third time this year as Zepbound sales soar

Published by MarketWatch · United States 1 h ago

The GLP-1 drug continues to dominate the market for prescription weight-loss drugs in the U.S.

Read the full article on MarketWatch Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketwatch.com)

Also worth reading

Why Rising Rates Could Break the Bull Market Before AI Spending Can Save It

DoorDash GAAP EPS of $0.55 misses by $0.26, revenue of $4.6B

The Motley Fool

This Under-the-Radar Utility Just Signed a Massive Data Center Deal Without Anyone Noticing

Best Energy Stocks

CCC Intelligent Solutions Holdings earnings beat by $0.02, revenue topped estimates

GOOGL Tumbles Over 10% Premarket: Analyst Says Investors Underappreciate Alphabet’s AI Strength